Reametrix, a Bangalore-based company that provides basic research and assay development services to biotechnology and pharmaceutical companies, is scouting for strategic partners to take TriTstat, a critical diagnostic product for managing HIV patients, to the global markets.
Reametrix, incorporated five years ago with the purpose of ‘reverse innovation’, develops products to address human diagnostics in the domestic market.
“India will be the incubation point for our products which will then be rolled out across the global markets. We are in discussions with a few strategic partners for the purpose and expect to seal deals with them in the next 12 months,” Bala S Manian, founder of Reametrix, told Business Standard on the sidelines of the two-day International Knowledge Millennium Conference 2009 in Hyderabad.
Manian, who holds over 30 patents for electro-optical systems, said the company had developed TriTstat for drying reagents and chemicals, eliminating the cold chain. The product combines, formulates and unifies the chemicals, which is of interest to the West as the US Food and Drug Administration (US FDA)-approved product cuts labour costs too, he added.
“We are initially eyeing the African market and our product already has validation in Canada. We are now in the process of expanding TriTstat to veterinary diagnostics,” Manian said, adding the company was also bidding for government tenders.
Reametrix has the capabilities to develop 100 different products a year at its 20,000 sq ft facility in Bangalore. It presently has about 15 PhDs among its 40-strong research and development workforce.
